Tauroursodeoxycholic acid alleviates secondary injury in the spinal cord via up-regulation of CIBZ gene
- 131 Downloads
Spinal cord injury (SCI) is generally divided into primary and secondary injuries, and apoptosis is an important event of the secondary injury. As an endogenous bile acid and recognized endoplasmic reticulum (ER) stress inhibitor, tauroursodeoxycholic acid (TUDCA) administration has been reported to have a potentially therapeutic effect on neurodegenerative diseases, but its real mechanism is still unclear. In this study, we evaluated whether TUDCA could alleviate traumatic damage of the spinal cord and improve locomotion function in a mouse model of SCI. Traumatic SCI mice were intraperitoneally injected with TUDCA, and the effects were evaluated based on motor function assessment, histopathology, apoptosis detection, qRT-PCR, and western blot at different time periods. TUDCA administration can improve motor function and reduce secondary injury and lesion area after SCI. Furthermore, the apoptotic ratios were significantly reduced; Grp78, Erdj4, and CHOP were attenuated by the treatment. Unexpectedly, the levels of CIBZ, a novel therapeutic target for SCI, were specifically up-regulated. Taken together, it is suggested that TUDCA effectively suppressed ER stress through targeted up-regulation of CIBZ. This study also provides a new strategy for relieving secondary damage by inhibiting apoptosis in the early treatment of spinal cord injury.
KeywordsTauroursodeoxycholic acid Spinal cord injury ER stress Apoptosis CIBZ
This study was supported by the National Natural Science Foundation of China (NSFC, 31372207 and 81570094), the Innovation Team of Scientific Research Platform in Anhui Province, a start-up grant from Nanjing Agricultural University (804090), and the “Sanxin” Research Program of Jiangsu Province (SXGC312).
Compliance with ethical standards
All animal experiments complied with the ARRIVE guidelines and were carried out according to the National Institutes of Health guide for the care and use of laboratory animals. All animal experiments were approved by the Anhui Normal University Academic Ethics Committee.
- Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC (2002) Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington’s disease. Proc Natl Acad Sci U S A 99:10671–10676. https://doi.org/10.1073/pnas.162362299 CrossRefPubMedPubMedCentralGoogle Scholar
- Ramalho RM, Ribeiro PS, Sola S, Castro RE, Steer CJ, Rodrigues CM (2004) Inhibition of the E2F-1/p53/Bax pathway by tauroursodeoxycholic acid in amyloid beta-peptide-induced apoptosis of PC12 cells. J Neurochem 90:567–575. https://doi.org/10.1111/j.1471-4159.2004.02517.x CrossRefPubMedGoogle Scholar
- Rodrigues CM, Sola S, Nan Z, Castro RE, Ribeiro PS, Low WC, Steer CJ (2003) Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proc Natl Acad Sci U S A 100:6087–6092. https://doi.org/10.1073/pnas.1031632100 CrossRefPubMedPubMedCentralGoogle Scholar
- Shuda M, Kondoh N, Imazeki N, Tanaka K, Okada T, Mori K, Hada A, Arai M, Wakatsuki T, Matsubara O, Yamamoto N, Yamamoto M (2003) Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. J Hepatol 38:605–614CrossRefPubMedGoogle Scholar
- Wang C, Liu C, Gao K, Zhao H, Zhou Z, Shen Z, Guo Y, Li Z, Yao T, Mei X (2016) Metformin preconditioning provide neuroprotection through enhancement of autophagy and suppression of inflammation and apoptosis after spinal cord injury. Biochem Biophys Res Commun 477:534–540. https://doi.org/10.1016/j.bbrc.2016.05.148 CrossRefPubMedGoogle Scholar
- Yanguas-Casas N, Barreda-Manso MA, Perez-Rial S, Nieto-Sampedro M, Romero-Ramirez L (2016) TGFbeta contributes to the anti-inflammatory effects of tauroursodeoxycholic acid on an animal model of acute neuroinflammation. Mol Neurobiol. https://doi.org/10.1007/s12035-016-0142-6